clonazepam has been researched along with Burning Mouth Syndrome in 46 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
Burning Mouth Syndrome: A group of painful oral symptoms associated with a burning or similar sensation. There is usually a significant organic component with a degree of functional overlay; it is not limited to the psychophysiologic group of disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Comparison between low-level laser therapy (LLLT) and clonazepam for treating burning mouth syndrome (BMS) patients has never been documented; the aim of this study was to assess the effects of LLLT photobiomodulation versus medical therapy with clonazepam on BMS." | 9.22 | A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome. ( Arduino, PG; Broccoletti, R; Cabras, M; Cafaro, A; Gambino, A; Garrone, M; Romagnoli, E, 2016) |
| "Clonazepam has been used in the treatment of burning mouth syndrome (BMS) for several decades." | 8.93 | Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis. ( Chen, FM; Chen, QM; Cui, Y; Jiang, L; Liu, JL; Xu, H; Zhou, Y, 2016) |
| "This study was intended to evaluate the clinical efficacy of a combination of N-acetylcysteine (NAC) and clonazepam for treatment of burning mouth syndrome (BMS)." | 8.02 | Use of a combination of N-acetylcysteine and clonazepam to treat burning mouth syndrome. ( Bang, J; Cho, JH; Han, S; Lim, JH, 2021) |
| "This retrospective study aimed to evaluate the efficacy of clonazepam and amitriptyline in the treatment of burning mouth syndrome (BMS)." | 7.85 | Pain-relieving effects of clonazepam and amitriptyline in burning mouth syndrome: a retrospective study. ( Arrive, E; Catros, S; Fenelon, M; Fricain, JC; Quinque, E, 2017) |
| "The study was a retrospective chart review of patients diagnosed with oral dysesthesia and managed with topical clonazepam solution (swish and spit) between 2008 and 2015." | 7.85 | Safety and tolerability of topical clonazepam solution for management of oral dysesthesia. ( Ji, YD; Kelley, JM; Kuten-Shorrer, M; Lerman, MA; Palmason, S; Sonis, ST; Stock, S; Treister, NS; Villa, A; Woo, SB, 2017) |
| "To evaluate retrospectively the efficacy of administering an anticonvulsant medication, clonazepam, by dissolving tablets slowly orally before swallowing, for the management of burning mouth syndrome (BMS)." | 7.77 | Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: a retrospective pilot study. ( Amos, K; Farah, CS; Yeoh, SC, 2011) |
| "The results suggest that clonazepam may be helpful in burning mouth syndrome, inasmuch as 70% of patients (groups 1 and 2) experienced pain reduction with effects at low doses." | 7.70 | An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. ( Epstein, J; Grushka, M; Mott, A, 1998) |
| " In the former, the oral dosage of clonazepam 0." | 7.11 | Comparison of Clonazepam and Tongue Protector in the Treatment of Burning Mouth Syndrome. ( Konopka, T; Zborowski, J, 2022) |
| "In the treatment of burning mouth syndrome (BMS), various approaches have been tried with equivocal results." | 6.77 | A double-blind study on clonazepam in patients with burning mouth syndrome. ( Grushka, M; Heckmann, SM; Hummel, T; Kirchner, E; Wichmann, MG, 2012) |
| "Clonazepam has been widely prescribed and is effective, but it is unclear whether clonazepam also affects the symptoms that accompany BMS, or whether such symptoms affect treatment outcomes." | 5.91 | Therapeutic effects of clonazepam in patients with burning mouth syndrome and various symptoms or psychological conditions. ( Bang, JI; Kim, GJ; Kim, MR; Kim, SY; Shin, HI; Sun, DI, 2023) |
| "The purpose of this study is to apply a machine learning approach to predict whether patients with burning mouth syndrome (BMS) respond to the initial approach and clonazepam therapy based on clinical data." | 4.02 | Prediction of treatment outcome in burning mouth syndrome patients using machine learning based on clinical data. ( Kho, HS; Kim, HG; Kim, MJ; Kim, PJ, 2021) |
| " The Numeric Rating Scale (NRS), the Total Pain Rating Index (T-PRI), the Hamilton rating scales for Depression (HAM-D) and Anxiety (HAM-A) were performed at baseline (time 0), after 2 months of topical clonazepam (time 1) and after 6 months of benzodiazepine and antidepressant drugs (time 2)." | 3.88 | Management of reticular oral lichen planus patients with burning mouth syndrome-like oral symptoms: a pilot study. ( Adamo, D; Aria, M; Fortuna, G; Mignogna, MD; Pecoraro, G, 2018) |
| "The study was a retrospective chart review of patients diagnosed with oral dysesthesia and managed with topical clonazepam solution (swish and spit) between 2008 and 2015." | 3.85 | Safety and tolerability of topical clonazepam solution for management of oral dysesthesia. ( Ji, YD; Kelley, JM; Kuten-Shorrer, M; Lerman, MA; Palmason, S; Sonis, ST; Stock, S; Treister, NS; Villa, A; Woo, SB, 2017) |
| "The results suggest that clonazepam may be helpful in burning mouth syndrome, inasmuch as 70% of patients (groups 1 and 2) experienced pain reduction with effects at low doses." | 3.70 | An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. ( Epstein, J; Grushka, M; Mott, A, 1998) |
| " In the former, the oral dosage of clonazepam 0." | 3.11 | Comparison of Clonazepam and Tongue Protector in the Treatment of Burning Mouth Syndrome. ( Konopka, T; Zborowski, J, 2022) |
| "Burning mouth syndrome is a chronic idiopathic intractable intraoral dysaesthesia that remains a challenge to clinicians due to its poorly understood pathogenesis and inconsistent response to various treatments." | 2.82 | A systematic review of treatment for patients with burning mouth syndrome. ( Hoffmann, J; Renton, T; Smith, JG; Tan, HL, 2022) |
| "Gabapentin was seen in one study to work alone and synergistically with ALA." | 2.58 | Burning mouth syndrome: a systematic review of treatments. ( Han, P; Inman, JC; Kim, Y; Liu, YF; Yoo, T, 2018) |
| "As in neuropathic pain, decreased brain activation to heat stimuli has been demonstrated with fMRI in BMS patients." | 2.48 | Pathophysiology of primary burning mouth syndrome. ( Jääskeläinen, SK, 2012) |
| "Clonazepam has been widely prescribed and is effective, but it is unclear whether clonazepam also affects the symptoms that accompany BMS, or whether such symptoms affect treatment outcomes." | 1.91 | Therapeutic effects of clonazepam in patients with burning mouth syndrome and various symptoms or psychological conditions. ( Bang, JI; Kim, GJ; Kim, MR; Kim, SY; Shin, HI; Sun, DI, 2023) |
| "Clonazepam was administered as the first-line medication." | 1.62 | Treatment outcomes and related clinical characteristics in patients with burning mouth syndrome. ( Kho, HS; Kim, J; Kim, MJ, 2021) |
| "Burning Mouth Syndrome (BMS) is a chronic pain condition characterized by persistent intraoral burning without related objective findings and unknown etiology that affects elderly females mostly." | 1.46 | Refractory burning mouth syndrome: clinical and paraclinical evaluation, comorbiities, treatment and outcome. ( Deligianni, CI; Ljubisavljevic, S; Mitsikostas, DD, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.35) | 18.2507 |
| 2000's | 9 (19.57) | 29.6817 |
| 2010's | 25 (54.35) | 24.3611 |
| 2020's | 10 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Han, S | 1 |
| Lim, JH | 1 |
| Bang, J | 1 |
| Cho, JH | 1 |
| Rossella, I | 1 |
| Alessandro, V | 1 |
| Naman, R | 1 |
| Gary, K | 1 |
| Hervé, SY | 1 |
| Sangalli, L | 1 |
| Miller, CS | 2 |
| Zborowski, J | 1 |
| Konopka, T | 1 |
| Alvarenga-Brant, R | 1 |
| Costa, FO | 1 |
| Mattos-Pereira, G | 1 |
| Esteves-Lima, RP | 1 |
| Belém, FV | 1 |
| Lai, H | 1 |
| Ge, L | 1 |
| Gomez, RS | 1 |
| Martins, CC | 1 |
| Shin, HI | 1 |
| Bang, JI | 1 |
| Kim, GJ | 1 |
| Kim, MR | 1 |
| Sun, DI | 1 |
| Kim, SY | 1 |
| Kim, MJ | 2 |
| Kim, J | 1 |
| Kho, HS | 3 |
| Suga, T | 1 |
| Tu, TTH | 1 |
| Nagamine, T | 1 |
| Toyofuku, A | 1 |
| Kim, PJ | 1 |
| Kim, HG | 1 |
| Tan, HL | 1 |
| Smith, JG | 1 |
| Hoffmann, J | 1 |
| Renton, T | 1 |
| Mitsikostas, DD | 1 |
| Ljubisavljevic, S | 1 |
| Deligianni, CI | 1 |
| Fenelon, M | 1 |
| Quinque, E | 1 |
| Arrive, E | 1 |
| Catros, S | 1 |
| Fricain, JC | 1 |
| Kuten-Shorrer, M | 1 |
| Treister, NS | 1 |
| Stock, S | 1 |
| Kelley, JM | 1 |
| Ji, YD | 1 |
| Woo, SB | 1 |
| Lerman, MA | 1 |
| Palmason, S | 1 |
| Sonis, ST | 1 |
| Villa, A | 1 |
| Adamo, D | 1 |
| Mignogna, MD | 1 |
| Pecoraro, G | 1 |
| Aria, M | 1 |
| Fortuna, G | 1 |
| Oberoi-Jassal, R | 1 |
| Portman, D | 1 |
| Smith, J | 1 |
| Rajasekhara, S | 1 |
| Desai, VV | 1 |
| Donovan, KA | 1 |
| Chang, YD | 1 |
| de Castro, LA | 1 |
| Ribeiro-Rotta, RF | 1 |
| Silvestre, FJ | 1 |
| Silvestre-Rangil, J | 1 |
| López-Jornet, P | 1 |
| Jurisic Kvesic, A | 1 |
| Zavoreo, I | 1 |
| Basic Kes, V | 1 |
| Vucicevic Boras, V | 1 |
| Ciliga, D | 1 |
| Gabric, D | 1 |
| Vrdoljak, DV | 1 |
| Cui, Y | 1 |
| Xu, H | 1 |
| Chen, FM | 1 |
| Liu, JL | 1 |
| Jiang, L | 1 |
| Zhou, Y | 1 |
| Chen, QM | 1 |
| Salerno, C | 1 |
| Di Stasio, D | 1 |
| Petruzzi, M | 1 |
| Lauritano, D | 1 |
| Gentile, E | 1 |
| Guida, A | 1 |
| Maio, C | 1 |
| Tammaro, M | 1 |
| Serpico, R | 1 |
| Lucchese, A | 1 |
| Arduino, PG | 1 |
| Cafaro, A | 1 |
| Garrone, M | 1 |
| Gambino, A | 1 |
| Cabras, M | 1 |
| Romagnoli, E | 1 |
| Broccoletti, R | 1 |
| Liu, YF | 1 |
| Kim, Y | 1 |
| Yoo, T | 1 |
| Han, P | 1 |
| Inman, JC | 1 |
| Speciali, JG | 1 |
| Stuginski-Barbosa, J | 1 |
| Buchanan, J | 1 |
| Zakrzewska, J | 1 |
| Grémeau-Richard, C | 2 |
| Dubray, C | 1 |
| Aublet-Cuvelier, B | 1 |
| Ughetto, S | 1 |
| Woda, A | 3 |
| Gibbs, J | 1 |
| Barker, KE | 1 |
| Batstone, MD | 1 |
| Savage, NW | 1 |
| Buchanan, JA | 1 |
| Zakrzewska, JM | 1 |
| Martin, WJ | 1 |
| Forouzanfar, T | 1 |
| Amos, K | 1 |
| Yeoh, SC | 1 |
| Farah, CS | 1 |
| Jääskeläinen, SK | 1 |
| Hens, MJ | 1 |
| Alonso-Ferreira, V | 1 |
| Villaverde-Hueso, A | 1 |
| Abaitua, I | 1 |
| Posada de la Paz, M | 1 |
| de Moraes, M | 1 |
| do Amaral Bezerra, BA | 1 |
| da Rocha Neto, PC | 1 |
| de Oliveira Soares, AC | 1 |
| Pinto, LP | 1 |
| de Lisboa Lopes Costa, A | 1 |
| Heckmann, SM | 1 |
| Kirchner, E | 1 |
| Grushka, M | 3 |
| Wichmann, MG | 1 |
| Hummel, T | 1 |
| Kim, HI | 1 |
| Kim, YY | 1 |
| Chang, JY | 1 |
| Ko, JY | 1 |
| Forssell, H | 1 |
| Teerijoki-Oksa, T | 1 |
| Kotiranta, U | 1 |
| Kantola, R | 1 |
| Bäck, M | 1 |
| Vuorjoki-Ranta, TR | 1 |
| Siponen, M | 1 |
| Leino, A | 1 |
| Puukka, P | 1 |
| Estlander, AM | 1 |
| Rodríguez de Rivera Campillo, E | 1 |
| López-López, J | 1 |
| Chimenos-Küstner, E | 1 |
| Gerlinger, I | 1 |
| Danhauer, SC | 1 |
| Rhodus, NL | 1 |
| Carlson, CR | 1 |
| Navez, ML | 2 |
| Attal, N | 1 |
| Bouhassira, D | 1 |
| Gagnieu, MC | 1 |
| Laluque, JF | 1 |
| Picard, P | 2 |
| Pionchon, P | 1 |
| Tubert, S | 1 |
| Bartoshuk, LM | 1 |
| Snyder, DJ | 1 |
| Berger, AM | 1 |
| Duffy, VB | 1 |
| Kveton, JF | 1 |
| Schatton, R | 1 |
| Riechelmann, H | 1 |
| Femiano, F | 1 |
| Lanza, A | 1 |
| Buonaiuto, C | 1 |
| Gombos, F | 1 |
| Nunziata, M | 1 |
| Cuccurullo, L | 1 |
| Cirillo, N | 1 |
| Epstein, J | 1 |
| Mott, A | 1 |
| Gremeau, C | 1 |
| Pichard-Leandri, E | 1 |
| Perno, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Study on the Treatment of Burning Mouth Syndrome With Integration of Traditional Chinese Medicine(TCM) and Western Medicine Based on TCM Syndrome Differentiation[NCT04189367] | Phase 3 | 80 participants (Anticipated) | Interventional | 2020-06-20 | Not yet recruiting | ||
| Study Evaluating the Laser Diode Effect on Burning Mouth Syndrome[NCT02757612] | 30 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Use of Low Intensity Laser Combined With Topical Clonazepam for the Treatment of Burning Mouth Syndrome[NCT04313907] | Phase 4 | 27 participants (Anticipated) | Interventional | 2019-08-16 | Recruiting | ||
| COMPARATIVE ANALYSIS OF THE TREATMENT OF BURNING MOUTH WITH LOW-INTENSITY LASER THERAPY AND TRANSCUTANEOUS ELECTRICAL NERVOUS STIMULATION: RANDOMIZED CLINICAL TRIAL[NCT05816200] | 25 participants (Actual) | Interventional | 2021-04-01 | Completed | |||
| Burning Mouth Disorder (BMD) - a Neuropathic Pain Disorder? An Investigation Using Qualitative and Quantitative Sensory Testing (QST)[NCT00504387] | 12 participants (Anticipated) | Observational | 2007-04-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for clonazepam and Burning Mouth Syndrome
| Article | Year |
|---|---|
Treatments for Burning Mouth Syndrome: A Network Meta-analysis.
Topics: Burning Mouth Syndrome; Clonazepam; Humans; Network Meta-Analysis; Pain; Quality of Life | 2023 |
A systematic review of treatment for patients with burning mouth syndrome.
Topics: Burning Mouth Syndrome; Capsaicin; Clonazepam; Humans; Pain; Thioctic Acid | 2022 |
Burning mouth syndrome: a review and update.
Topics: Adult; Age Distribution; Aged; Algorithms; Amisulpride; Antidepressive Agents; Burning Mouth Syndrom | 2015 |
Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Humans; Middle Aged; Remission Induction | 2016 |
An overview of burning mouth syndrome.
Topics: Benzylamines; Burning Mouth Syndrome; Capsaicin; Clonazepam; Humans; Lidocaine; Prevalence | 2016 |
Burning mouth syndrome: a systematic review of treatments.
Topics: Amines; Analgesics; Antioxidants; Burning Mouth Syndrome; Capsaicin; Clonazepam; Cyclohexanecarboxyl | 2018 |
Burning mouth syndrome.
Topics: Administration, Oral; Burning Mouth Syndrome; Clonazepam; Dopamine Agonists; Female; Humans; Male; M | 2008 |
Burning mouth syndrome.
Topics: Antidepressive Agents; Benzodiazepines; Burning Mouth Syndrome; Clonazepam; Humans | 2008 |
Burning mouth syndrome.
Topics: Antidepressive Agents; Benzodiazepines; Burning Mouth Syndrome; Clonazepam; Cognitive Behavioral The | 2010 |
The efficacy of anticonvulsants on orofacial pain: a systematic review.
Topics: Amines; Anticonvulsants; Burning Mouth Syndrome; Carbamazepine; Clonazepam; Cyclohexanecarboxylic Ac | 2011 |
Pathophysiology of primary burning mouth syndrome.
Topics: Anesthetics, Local; Burning Mouth Syndrome; Clonazepam; Female; Functional Neuroimaging; Humans; Lid | 2012 |
Randomized trials for the treatment of burning mouth syndrome: an evidence-based review of the literature.
Topics: Antioxidants; Burning Mouth Syndrome; Capsaicin; Clonazepam; Evidence-Based Dentistry; GABA Modulato | 2012 |
[Burning sensation in oral cavity--burning mouth syndrome in everyday medical practice].
Topics: Acetamides; Amines; Anti-Anxiety Agents; Antidepressive Agents; Antioxidants; Burning Mouth Syndrome | 2012 |
Burning mouth syndrome.
Topics: Aging; Anticonvulsants; Burning Mouth Syndrome; Clonazepam; Estrogen Replacement Therapy; Female; Hu | 2001 |
10 trials available for clonazepam and Burning Mouth Syndrome
| Article | Year |
|---|---|
Comparison of Clonazepam and Tongue Protector in the Treatment of Burning Mouth Syndrome.
Topics: Burning Mouth Syndrome; Clonazepam; Female; Humans; Quality of Life; Sleep Initiation and Maintenanc | 2022 |
The effect of clonazepam mouthwash on the symptomatology of burning mouth syndrome: an open pilot study.
Topics: Adult; Aged; Burning Mouth Syndrome; Clonazepam; Female; GABA Modulators; Humans; Male; Middle Aged; | 2014 |
The effectiveness of acupuncture versus clonazepam in patients with burning mouth syndrome.
Topics: Acupuncture Therapy; Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Male; Middle Aged; Pa | 2015 |
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Lasers, Semiconductor; Low-Level Light The | 2016 |
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Lasers, Semiconductor; Low-Level Light The | 2016 |
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Lasers, Semiconductor; Low-Level Light The | 2016 |
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Lasers, Semiconductor; Low-Level Light The | 2016 |
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Lasers, Semiconductor; Low-Level Light The | 2016 |
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Lasers, Semiconductor; Low-Level Light The | 2016 |
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Lasers, Semiconductor; Low-Level Light The | 2016 |
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Lasers, Semiconductor; Low-Level Light The | 2016 |
A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndrome.
Topics: Aged; Burning Mouth Syndrome; Clonazepam; Female; Humans; Lasers, Semiconductor; Low-Level Light The | 2016 |
Effect of lingual nerve block on burning mouth syndrome (stomatodynia): a randomized crossover trial.
Topics: Anticonvulsants; Burning Mouth Syndrome; Clonazepam; Cross-Over Studies; Double-Blind Method; Female | 2010 |
A double-blind study on clonazepam in patients with burning mouth syndrome.
Topics: Administration, Oral; Aged; Burning Mouth Syndrome; Clonazepam; Dose-Response Relationship, Drug; Do | 2012 |
A double-blind study on clonazepam in patients with burning mouth syndrome.
Topics: Administration, Oral; Aged; Burning Mouth Syndrome; Clonazepam; Dose-Response Relationship, Drug; Do | 2012 |
A double-blind study on clonazepam in patients with burning mouth syndrome.
Topics: Administration, Oral; Aged; Burning Mouth Syndrome; Clonazepam; Dose-Response Relationship, Drug; Do | 2012 |
A double-blind study on clonazepam in patients with burning mouth syndrome.
Topics: Administration, Oral; Aged; Burning Mouth Syndrome; Clonazepam; Dose-Response Relationship, Drug; Do | 2012 |
Response to topical clonazepam in patients with burning mouth syndrome: a clinical study.
Topics: Administration, Topical; Aged; Aged, 80 and over; Burning Mouth Syndrome; Chi-Square Distribution; C | 2010 |
Impact of criteria-based diagnosis of burning mouth syndrome on treatment outcome.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Anticonvulsants; Burning Mouth Syndrome; Carbam | 2002 |
Topical clonazepam in stomatodynia: a randomised placebo-controlled study.
Topics: Administration, Topical; Aged; Anticonvulsants; Burning Mouth Syndrome; Clonazepam; Double-Blind Met | 2004 |
A possible therapeutic solution for stomatodynia (burning mouth syndrome).
Topics: Adult; Aged; Aged, 80 and over; Burning Mouth Syndrome; Clonazepam; Facial Pain; Female; GABA Modula | 1998 |
22 other studies available for clonazepam and Burning Mouth Syndrome
| Article | Year |
|---|---|
Use of a combination of N-acetylcysteine and clonazepam to treat burning mouth syndrome.
Topics: Acetylcysteine; Burning Mouth Syndrome; Clonazepam; Humans; Quality of Life; Surveys and Questionnai | 2021 |
Topical clonazepam for burning mouth syndrome: Is it efficacious in patients with anxiety or depression?
Topics: Anxiety; Burning Mouth Syndrome; Clonazepam; Depression; Humans; Retrospective Studies | 2022 |
Low-dose naltrexone for treatment of burning mouth syndrome.
Topics: Burning Mouth Syndrome; Clonazepam; Female; Fibromyalgia; Headache; Humans; Middle Aged; Naltrexone; | 2023 |
Therapeutic effects of clonazepam in patients with burning mouth syndrome and various symptoms or psychological conditions.
Topics: Burning Mouth Syndrome; Clonazepam; Dysgeusia; Humans; Pain; Retrospective Studies; Xerostomia | 2023 |
Treatment outcomes and related clinical characteristics in patients with burning mouth syndrome.
Topics: Burning Mouth Syndrome; Clonazepam; Gabapentin; Humans; Retrospective Studies; Treatment Outcome | 2021 |
Careful use of clonazepam and alpha lipoid acid in burning mouth syndrome treatment.
Topics: Burning Mouth Syndrome; Clonazepam; Humans | 2022 |
Prediction of treatment outcome in burning mouth syndrome patients using machine learning based on clinical data.
Topics: Burning Mouth Syndrome; Clonazepam; Female; Humans; Lubricants; Machine Learning; Male; Middle Aged; | 2021 |
Refractory burning mouth syndrome: clinical and paraclinical evaluation, comorbiities, treatment and outcome.
Topics: Aged; Anticonvulsants; Anxiety; Burning Mouth Syndrome; Chronic Disease; Chronic Pain; Clonazepam; C | 2017 |
Pain-relieving effects of clonazepam and amitriptyline in burning mouth syndrome: a retrospective study.
Topics: Aged; Amitriptyline; Analgesics, Non-Narcotic; Burning Mouth Syndrome; Clonazepam; Female; GABA Modu | 2017 |
Safety and tolerability of topical clonazepam solution for management of oral dysesthesia.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Burning Mouth Syndrome; Clonaze | 2017 |
Management of reticular oral lichen planus patients with burning mouth syndrome-like oral symptoms: a pilot study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Anxiety; Benzodiazepines; Burning Mouth Syndrome; Cl | 2018 |
Burning Mouth Pain: A Case Report.
Topics: Analgesics; Burning Mouth Syndrome; Carcinoma, Squamous Cell; Clonazepam; Female; Fentanyl; Gabapent | 2018 |
Commentary: a burning question of subgroup analysis in pain trials.
Topics: Anticonvulsants; Burning Mouth Syndrome; Clonazepam; Cross-Over Studies; Double-Blind Method; Female | 2010 |
Comparison of treatment modalities in burning mouth syndrome.
Topics: Anxiety; Burning Mouth Syndrome; Chi-Square Distribution; Clonazepam; Depression; Diazepam; Female; | 2009 |
Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: a retrospective pilot study.
Topics: Administration, Oral; Administration, Topical; Burning Mouth Syndrome; Clonazepam; Dental Audit; Fem | 2011 |
Cost-effectiveness analysis of burning mouth syndrome therapy.
Topics: Amisulpride; Antidepressive Agents; Burning Mouth Syndrome; Clonazepam; Cost-Benefit Analysis; Decis | 2012 |
Salivary cortisol, 17β-estradiol, progesterone, dehydroepiandrosterone, and α-amylase in patients with burning mouth syndrome.
Topics: Age Factors; Aged; alpha-Amylases; Burning Mouth Syndrome; Case-Control Studies; Clonazepam; Dehydro | 2012 |
Pain and pain behavior in burning mouth syndrome: a pain diary study.
Topics: Adaptation, Psychological; Analgesics; Analysis of Variance; Anticonvulsants; Antidepressive Agents, | 2012 |
Taste damage: previously unsuspected consequences.
Topics: Burning Mouth Syndrome; Clonazepam; Female; GABA Agonists; gamma-Aminobutyric Acid; Humans; Male; Mo | 2005 |
[Burning mouth syndrome].
Topics: Age Factors; Anticonvulsants; Burning Mouth Syndrome; Clonazepam; Cranial Nerve Diseases; Cross-Sect | 2007 |
Burning mouth syndrome and burning mouth in hypothyroidism: proposal for a diagnostic and therapeutic protocol.
Topics: Adult; Aged; Antioxidants; Burning Mouth Syndrome; Case-Control Studies; Chi-Square Distribution; Cl | 2008 |
An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Burning Mouth Syndrome; Chronic Disease; Clonazepam; | 1998 |